Metformin suppresses adipocyte differentiation by increasing FGF21 expression in the liver and white adipocytes in an AMPK-independent way, thus eliciting its therapeutic effect on T2DM, obesity and fatty liver [125, 185]. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.